ABOUT US /
Active since 1997, Aksìa SGR is a private equity fund that invests mainly in medium-sized Italian companies, promoting their growth and international development
CASE STUDY
SELECT CASE STUDY
CONTENT GROUP
CONTENT GROUP
Content Group is a leading European CDMO in the production of liquid sterile medical devices and pharmaceuticals for the ophthalmic market. Thanks to the reinforcement of the management team, the redesigning of the commercial strategy and the strengthening of research and development activities, particularly for new private-label products, COC Farmaceutici is today the leading group in the Italian market and a well-positioned CDMO player in Europe. Moreover, since the entry of Aksìa, with over €25m invested in capex on three production plants, two of which are authorised by AIFA and one by the FDA ,17 production lines and over 500 employees, the Group has significantly consolidated its competitive position in the reference market over the recent years
turnover
sector
healthcare
date of acquisition
2016
annual sales growth
18.3%
annual ebitda growth
22.4%
VALSA GROUP
VALSA GROUP
Creation of a leading Italian group in the production and marketing of fresh and frozen pizza, focaccia, pinsa and snacks through company acquisitions and integrations. The project foresees the strengthening of the management structure and the expansion of the customer base also through the opening of new geographical markets. Since the entry of Aksìa, the Valsa Group has completed 4 strategic add-ons to diversify the portfolio offer and has strongly increased sales abroad, which have reached approximately 50% of turnover. Today, Valsa is the most diversified player in the market, able to serve all channels with both branded and private-label products
turnover
sector
food
date of acquisition
2020
annual sales growth
67.7%
annual ebitda growth
69.4%
PCG
PCG
Creation of a leading Italian group in the rapidly growing market of dental clinics through acquisitions, integrations and organic expansion. Since Aksìa acquisition, PCG has developed more than 25 green fields new openings and completed 5 major add-ons that led the group from 42 to 160 clinics. Through the merger of Primo Group, Oasi Medica and CareDent, Aksìa has created the second player in the Italian dental clinic market and the first Italian group to launch a brand extension to outpatient clinics. In addition, the merger enhanced brand perception throughout Italy and significantly improved processes with a direct impact on performance and the long-term sustainability of the Group
turnover
sector
healthcare
date of acquisition
2019
annual sales growth
35.8%
annual ebitda growth
34.4%
MIR
MIR
Develop a unique, vertically integrated business in the spirometry and telemedicine markets, operating in over 100 countries. Aksìa acquired MIR from the founders with the aim of leading the company through its next stage of development. In particular, the project involves strengthening the management structure, sales and research and development functions to consolidate its presence in the market in which it currently operates and to enter new markets. After the entry of Aksìa, MIR significantly redesigned its commercial strategy, also through the opening of two foreign subsidiaries, and strongly streamlined its sourcing strategy. This has led to strong organic growth in terms of both top line and profitability
turnover
sector
healthcare
date of acquisition
2021
annual sales growth
20.6%
annual ebitda growth
30.6%
CASE STUDY /
CONTENT GROUP
CONTENT GROUP
CONTENT GROUP
Content Group is a leading European CDMO in the production of liquid sterile medical devices and pharmaceuticals for the ophthalmic market. Thanks to the reinforcement of the management team, the redesigning of the commercial strategy and the strengthening of research and development activities, particularly for new private-label products, COC Farmaceutici is today the leading group in the Italian market and a well-positioned CDMO player in Europe. Moreover, since the entry of Aksìa, with over €25m invested in capex on three production plants, two of which are authorised by AIFA and one by the FDA ,17 production lines and over 500 employees, the Group has significantly consolidated its competitive position in the reference market over the recent years
turnover
sector
healthcare
annual sales growth
18.3%
date of acquisition
2016
annual ebitda growth
22.4%
VALSA GROUP
VALSA GROUP
VALSA GROUP
Creation of a leading Italian group in the production and marketing of fresh and frozen pizza, focaccia, pinsa and snacks through company acquisitions and integrations. The project foresees the strengthening of the management structure and the expansion of the customer base also through the opening of new geographical markets. Since the entry of Aksìa, the Valsa Group has completed 4 strategic add-ons to diversify the portfolio offer and has strongly increased sales abroad, which have reached approximately 50% of turnover. Today, Valsa is the most diversified player in the market, able to serve all channels with both branded and private-label products.
turnover
sector
food
annual sales growth
67.7%
date of acquisition
2020
annual ebitda growth
69.4%
PCG
PCG
PCG
Creation of a leading Italian group in the rapidly growing market of dental clinics through acquisitions, integrations and organic expansion. Since Aksìa acquisition, PCG has developed more than 25 green fields new openings and completed 5 major add-ons that led the group from 42 to 160 clinics. Through the merger of Primo Group, Oasi Medica and CareDent, Aksìa has created the second player in the Italian dental clinic market and the first Italian group to launch a brand extension to outpatient clinics. In addition, the merger enhanced brand perception throughout Italy and significantly improved processes with a direct impact on performance and the long-term sustainability of the Group.
turnover
sector
healthcare
annual sales growth
35.8%
date of acquisition
2019
annual ebitda growth
34.4%
mir
mir
mir
Develop a unique, vertically integrated business in the spirometry and telemedicine markets, operating in over 100 countries. Aksìa acquired MIR from the founders with the aim of leading the company through its next stage of development. In particular, the project involves strengthening the management structure, sales and research and development functions to consolidate its presence in the market in which it currently operates and to enter new markets. After the entry of Aksìa, MIR significantly redesigned its commercial strategy, also through the opening of two foreign subsidiaries, and strongly streamlined its sourcing strategy. This has led to strong organic growth in terms of both top line and profitability.
turnover
sector
healthcare
annual sales growth
20.6%
date of acquisition
2021
annual ebitda growth
30.6%
CREATING
SUSTAINABLE
VALUE.
We aim to create sustainable value for our investors and stakeholders by integrating ESG criteria into the investment strategy and supporting portfolio companies in the transaction to innovative business models.
CREATING
SUSTAINABLE
VALUE.
We aim to create sustainable value for our investors and stakeholders by integrating ESG criteria into the investment strategy and supporting portfolio companies in the transaction to innovative business models.
INSIGHTS
SAVI ALIMENTARI JOINS THE ITALIAN FOOD EXCELLENCE GROUP
The Aksìa Capital V fund,...
Read moreData Convergence Initiative membership
Aksìa joins Private Equity industry’s...
Read moreThree new promotions in the team
Aksìa Sgr, a private equity...
Read moreNew Sustainability Report
Aksìa SGR presented the second...
Read moreAksia and the Kintek Group
Aksìa Capital V, a fund...
Read moreAKSÌA enters the capital of ICAM
Aksìa Capital V, a fund...
Read moreRe-branding for the Covisian Group
Covisian Group, a leader in...
Read moreAcquisition of Europlast, FGR and Samcla
Aksìa Capital V, a fund...
Read moreMenchetti Panificio Acquisition
Aksìa Capital V, a fund...
Read moreStrengthening the team
Strengthening of the Aksìa Group’s...
Read more